Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Active not recruiting 3Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Neuroblastoma 1Neoplasms 1Lymphoma 1

Interventions

TIC10 compound 3trastuzumab deruxtecan 2umbralisib 1ublituximab 1pembrolizumab 1infigratinib 1enfortumab vedotin 1duvelisib 1blinatumomab 1belumosudil 1Rituximab 1KD025 1Gemcitabine 1Crizotinib 1Cisplatin 1Carboplatin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Has announcements × Crizotinib × Clear all
NCT01121588 2025-01-23

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Pfizer

Phase 1 Terminated
44 enrolled 22 charts 1 FDA
CNSLymphoid

Lymphoma, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡